Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
Collin M. Blakely(City College of San Francisco), David R. Gandara(University of California, Davis), Bianca Bacaltos(University of California, San Francisco), Matthew A. Gubens(University of California, San Francisco), Lea Daran(University of California, San Francisco), Tianhong Li(VA Northern California Health Care System), Jonathan W. Riess(University of California Davis Medical Center), Trever G. Bivona(University of California, San Francisco), Steffany L. Lim(University of California Davis Medical Center)
Cited by 8
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k